Currently browsing: Inventions/Patents

Another US patent granted

5/24/2018: The background is important in appreciating the value of this patent. Before antibiotics, bacteria were free floating in the body as individual bacteria. There response to anti biotics was to mutate and or form colonies covered with a protective coating of a biofilm that the antibiotic could not penetrate. A total joint implant becomes infected when the first step the bacteria do is to produce a biofilm on the implant and from there, they grow the covered colony. This US patent is important in that the solution applied to a total joint implant blocks the attachment of a biofilm and therefor the bacteria remain vulnerable to the protocatechuic acid (PCA) which destroys the biofilm and the bacteria. This patent also provides a means to coat bandages in the manufacturing process. The PCA dries. When applied to a moist wound, the PCA is activated and kills the bacteria and causes would healing acceleration. Allowed Claims 1. A method of reducing growth or development of a biofilm on a surface, comprising: contacting the surface with a composition comprising about 10% to about 50% of an anthocyanin metabolite or an anthocyanidin metabolite selected from protocatechuic acid and 2,4,6-trihydroxybenzaldehyde and mixtures and combinations thereof, wherein the contacting step reduces an initial attachment of a biofilm or a biofilm forming microorganism to the surface, thereby reducing the growth or development of the biofilm on the surface. 2. The method of claim 1, wherein the biofilm forming microorganism is selected from a Pseudomonas aeruginosa and a Methicillin-resistant Staphylococcus aureus. 3. The method of claim 1, wherein the composition is selected from a liquid, a sanitizer, a disinfectant, a swab, a salve, soap, foam, cream, solution, gel, spray, powder, crystals, antibacterial treatments, wipes, a lotion and combinations thereof. 4. The method of claim 1, wherein the surface is selected from a solid surface, a smooth surface, a porous or semi-porous surface, and a cloth-like surface. 5. The method of claim 1, wherein the surface is on an implant, a bandage, a catheter, a dressing, a heart or vascular grafts, or a wound. 6. The method of claim 1, wherein the surface is a ceramic surface. 7. The method of claim 1, wherein the contacting step is selected from wiping the surface, spraying the surface, soaking the surface, imbedding crystals of the anthocyanin metabolite or an anthocyanidin metabolite on or in the surface, or applying a bandage or wound dressing impregnated with the composition to the surface. 8. The method of claim 1, wherein the anthocyanin metabolite or an anthocyanidin metabolite is present in an amount of from about 10% to about 40% by weight of the composition. 9. The method of claim 1, wherein the anthocyanin metabolite or an anthocyanidin metabolite is present in an amount of from about 20% to about 30% by weight of the composition. 10. The method of claim 1, wherein the anthocyanin metabolite or an anthocyanidin metabolite is protocatechuic acid. 11. The method of claim 1, wherein the surface is contacted with the composition for up to two years. 12. The method of claim 3, wherein the composition comprises protocatechuic acid or 2,4,6–trihydroxybenzaldehyde or a mixture or combination thereof dissolved in a solution. 13. The method of claim 12, wherein the solution further comprises a carrier. 14. The method of claim 13, wherein the carrier is selected from water, isopropyl alcohol, and ethyl alcohol. 15. The method of claim 14, wherein the isopropyl alcohol is present at a concentration of about 70% to about 91%. 16. The method of claim 14, wherein the solution comprises 10% to 30% protocatechuic acid dissolved in about 70% isopropyl alcohol.

Skin health patent issued

4/11/2018: The US Patent office issued # 9,925,152 B2 on March 27, 2018. This was a continuation of the parent patent 9,498,413 which claimed protocatechuic acid as a broad spectrum antibiotic and a wound healing accelerator. The additional claims indicated the collagen formation properties and potential to reduce scar formation. The clinical application may accompany cosmetic exfoliation and surgical dermabrasion yielding a form of skin wrinkle treatment. See these granted claims. 10. The method of claim 1 wherein the treating of the wound is a cosmetic method of treating skin to enhance skin healing, wherein the composition is administered topically, orally or by intradermal or subcutaneous injection to a skin tissue, wherein the composition promotes an effect selected from the group consisting of reducing inflammation, optimizing growth hormone production, and increasing collagen stimulation. 11. The method according to claim 1, wherein said administration further results in reduced scar formation.

My Comments on the Health Care Industry’s CEO’s Innovation Visions

2/16/2018: Alex Gorsky, the CEO of Johnson & Johnson recently made the following statements concerning where healthcare innovation is headed.  Here is what I think about each of his factors listed in bolding. There must be a sense of urgency.  This is rarely seen in health care because they are slow to change their culture or way of doing business.  Why is there no change?  The have been successful in doing what they always have done. This requires us to actually re-imagine Johnson & Johnson as a 132-year-old startup.  The cultural background and personalities of those who came up through this system does not allow them to imagine what it takes to be a start up; personal risk, handling failure, more time than anticipated, and the idea of trying again.                           One that embraces and acts on the best ideas.  This is unlikely to happen since “corporate’s” idea of the best ideas are ones that produce profit in the next quarter, not five years from now when they will be retired or at another company. One that is nimble and fast.  This is unlikely as the junior officers are not going to risk loosing their job by proposing an idea or plan that requires a fast and nimble approach to new products. They know that no one got to the top of “corporate” doing it this way. One that leverages technology to drive life-changing and life-saving innovation.  The risk adverse culture will never leverage as this word contains risk.  Let me give you an example.  There is a US patented way to coat total joint implants at the time of surgery to prevent attachment of biofilm bacterial colonies.  The major orthopedic industry will not take this on because of the estimate of 10 years and 50-150 million dollars to get through the FDA.  They cannot even entertain a known less expensive way in time and money to get there. One that focuses on being competitive always.  Being competitive means you are the fittest and fastest with the most mental toughness.  High profits inherent in the major medical companies never have required these characteristics and will not, because it has not been necessary to date for success. One that embraces transformative products.  The corporate mentality of the “Big Pharma” has ignored the nutraceutical industry which incidentally is growing very fast., One that has quality services.  This factor does exist with present managements, marketing, sales and distribution. One that has transparent pricing.  This is not likely as the R&D and cost of doing business is so high, it requires new blockbuster drugs for cancer to sell for up to $100,000 per patient treatment; yes $100,000.   This is not you new aspirin. One that has all the factors with the consumer top-of-mind.  If this was so it would not have been almost 30 years since introduction of a new antibiotic.  Why is this?  The cost to develop plus regulations would not allow the same profit margin as cancer or arthritis. Summary Insights: For safety, medical companies usually do acquisitions, not innovations.  After all they are in the business of making money.

Real Feel Gloves launch

2/9/2018: The Real Feel Glove initiative was launched at the PGA show in Orlando.  Web site is up at  The interesting aspect is the suggestions to so many performance enhancing applications; golf, basketball, football, sport shooting as in Olympics, fly fishing and even musical instruments. Presently doing testing on PGA tour for supporting evidence.  US patent has been granted.

You may not be the first to make a discovery

1/7/2018:  You may not be the first to make a discovery.  I loved this short video’s teaching moment.

High Cost of Drugs; Why?

4/27/17: Drugs are expensive for one main reason; cost of FDA regulations.  New drug submissions require a Phase I to show they are safe.  Then a Phase II of 500-1000 cases to show it works.  If still positive then a Phase III of 2000 to 10000 cases are required with at least a 2 year follow-up. Here are the facts.  Only 15% of drugs are approved.   85% fail, but unfortunately they fail in Phase III when the millions are spent.  So the drug companies must cover the cost of the 85% that fail in the charge for the 15% that pass. Cases in point: I have a patented means to reduce surgical infections by coating a total joint implant at time of surgery so that any bacteria or biofilm colony would be destroyed upon contact.   No total joint company is interested in that the cost of the FDA study would be 50 to 150 million dollars to attempt to gain approval.  There would be a humanitarian and societal benefit, but the companies are in business to make money. It was announced today that back in 2014, Roche spent $725 million upfront on Seragon Pharmaceuticals, but three years down the line, it has now canned work on its leading drug, ARN-810.  

Another Patent Granted

12/11/2016: US patent was granted. 9,498,413  Anti-microbials and methods of use thereof for would healing. November 22, 2016 This established that protocatechuic acid is a broad spectrum antibiotic.  I also secured this same reagent as one that promotes rapid wound healing. The application included 32 claims, but the US patent office only will review two or three at at time.  This makes their work easiler and the applicant has to pay again for each subsequent review.  I have been told, the US patent office is the only division of the Federal Government that makes money. So we will return to secure other claims for which we have scientific evidence; biofilm destroying reagent to coat implants and reduce infection; spray disinfectan, creams and soaps for killing bacteria on skin; i.e. Acne. The next hurdle is the regulations with the FDA and EPA before we could go to market. Good thing I am young.